跳至主要内容
临床试验/NCT00537524
NCT00537524已完成2 期

A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years

Novartis Vaccines2 个研究点 分布在 1 个国家目标入组 471 人开始时间: 2007年9月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
471
试验地点
2
主要终点
safety and tolerability of, and magnitude of antibody responses to two 0.5mL intramuscular injections of an H5N1 influenza vaccineapart

研究概览

简要总结

Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
6 Months 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects

排除标准

  • Receipt of Seasonal Influenza Vaccine for season 2007/2008
  • Receipt of another vaccine within 3 weeks before and after each vaccination
  • Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the adjuvant MF59 or a similar adjuvant
  • Children who are in the local recommendation for influenza vaccination due to underlying diseases

结局指标

主要结局

safety and tolerability of, and magnitude of antibody responses to two 0.5mL intramuscular injections of an H5N1 influenza vaccineapart

时间窗: administered 3 weeks apart

次要结局

  • safety and tolerability of, and magnitude of antibodies to one booster dose with a H5N1(12 months after primary immunization)
  • safety profile of a H5N1 compared to a seasonal flu vaccinepersistence of specific antibodies(12 months after primary immunization)

研究者

发起方
Novartis Vaccines
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验